A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization

Jose Baselga

doi:10.1016/S1535-6108(02)00098-3

A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization

Jose Baselga

Department of Medicine

Research output: Contribution to journal › Review article › Research › peer-review

39 Citations (Scopus)

Abstract

Preventing ligand-dependent ErbB2 receptor heterodimers by an anti-ErbB2 monoclonal antibody shuts down receptor signaling and has potent antitumor activity even in tumors that express low levels of ErbB2, a finding that could result in a larger number of patients benefiting from anti-ErbB2 therapies. Copyright © 2002 Cell Press.

Original language	English
Pages (from-to)	93-95
Journal	Cancer Cell
Volume	2
Issue number	2
DOIs	https://doi.org/10.1016/S1535-6108(02)00098-3
Publication status	Published - 1 Jan 2002

Access to Document

10.1016/S1535-6108(02)00098-3

Fingerprint Dive into the research topics of 'A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization'. Together they form a unique fingerprint.

Cite this

@article{0ddaad8881f54c3da39a854bdc156f5f,

title = "A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization",

abstract = "Preventing ligand-dependent ErbB2 receptor heterodimers by an anti-ErbB2 monoclonal antibody shuts down receptor signaling and has potent antitumor activity even in tumors that express low levels of ErbB2, a finding that could result in a larger number of patients benefiting from anti-ErbB2 therapies. Copyright {\textcopyright} 2002 Cell Press.",

author = "Jose Baselga",

year = "2002",

month = jan,

day = "1",

doi = "10.1016/S1535-6108(02)00098-3",

language = "English",

volume = "2",

pages = "93--95",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization

AU - Baselga, Jose

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Preventing ligand-dependent ErbB2 receptor heterodimers by an anti-ErbB2 monoclonal antibody shuts down receptor signaling and has potent antitumor activity even in tumors that express low levels of ErbB2, a finding that could result in a larger number of patients benefiting from anti-ErbB2 therapies. Copyright © 2002 Cell Press.

AB - Preventing ligand-dependent ErbB2 receptor heterodimers by an anti-ErbB2 monoclonal antibody shuts down receptor signaling and has potent antitumor activity even in tumors that express low levels of ErbB2, a finding that could result in a larger number of patients benefiting from anti-ErbB2 therapies. Copyright © 2002 Cell Press.

U2 - 10.1016/S1535-6108(02)00098-3

DO - 10.1016/S1535-6108(02)00098-3

M3 - Review article

VL - 2

SP - 93

EP - 95

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 2

ER -